Christoph Correll is currently Professor of Psychiatry and Molecular Medicine at the Hofstra Northwell School of Medicine, New York, NY, USA and Medical Director of the Recognition and Prevention (RAP) programme at the Zucker Hillside Hospital, New York, USA. He is a board certified general psychiatrist and child and adolescent psychiatrist.
Professor Correll’s research and clinical work focuses on the identification, characterization and treatment of adults and youths with severe psychiatric disorders. His areas of expertise include the prodrome, first episode, multi-episode and refractory illness phase of severe psychotic and mood disorders, including schizophrenia, bipolar disorder, major depression, as well as aggressive spectrum disorders. He further focuses on the risk-benefit evaluation of psychotropic medications, including the extent and mechanisms of cardiometabolic and neuromotor adverse effects.
Professor Correll has authored or co-authored over 200 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of 11 scientific journals. He is the principal investigator or Steering Committee member of several large, federally funded grants and has received over two dozen national and international research awards and fellowships for his work.
To contact GME, email us at [email protected]